Knee Prosthetic Joint Infection Antibiotic Elution
Launched by UNIVERSITY OF PITTSBURGH · Aug 31, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how well an antibiotic spacer works for patients with infections in their knee replacement joints. Researchers will closely observe how patients respond to this treatment and measure the levels of antibiotics released into the joint area after surgery. They will also look at any complications that may arise after the procedure, including the need for additional surgeries or hospital readmissions.
To be eligible for this trial, participants must be at least 18 years old and scheduled to receive treatment for a knee joint infection. They should also be able to give their consent to participate. The trial is not yet recruiting participants, but once it begins, those involved can expect to be monitored for their recovery and any side effects related to the antibiotic treatment. This study aims to improve the understanding of how to effectively treat these types of infections in knee replacements.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients planned for treatment of a total knee arthroplasty prosthetic joint infection
- • Patients greater than 18 years of age
- • Patients able to provide informed consent
- Exclusion Criteria:
- • Prior history of ipsilateral or contralateral prosthetic joint infection warranting operative management
- • Patients less than 18 years of age
- • Patients unable to provide informed consent.
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Johannes F Plate, MD, PhD
Principal Investigator
University of Pittsburgh Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported